All In Biotech

Investigational drug · Phase 3

Rondecabtagene autoleucel

Also called: LYL314

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Rondecabtagene autoleucel"

First trial start

2023

May 9, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Rondecabtagene autoleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Lymphoma, B-Cell
  • Non-Hodgkin Lymphoma Refractory/ Relapsed
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B Cell Lymphoma Relapsed

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Rondecabtagene autoleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Relapsed Non-Hodgkin Lymphoma

  • EB103Phase 21 trial

    Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell

  • IDP-023Phase 21 trial

    Indapta Therapeutics, INC. · NHL, Multiple Myeloma, Blood Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.